Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017
November 8, 2017 4:07 PM ESTRANCHO CUCAMONGA, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended September 30, 2017.
Third Quarter Highlights
Net revenues of $57.9 million for the third quarterGAAP net income of $0.2 million, or $0.00 per diluted share, for the third quarterAdjusted non-GAAP net income of $3.5 million, or $0.07 per diluted share, for the third quarterDr. Jack Zhang, Amphastars CEO, commented: The third quarter was a successful one for Amphastar with approvals of both sodium bicarbonate and neostigmine. Approvals like these will... More
